Androgen Receptor Pathway Inhibitor Monotherapy in Prostate Cancer: Safety, Oncologic Outcomes, and Quality of Life—A Systematic Review and Meta-analysis
European Urology Focus · 2026-01 · 12 (1) · 109-130
DOI: 10.1016/j.euf.2025.05.006 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Urology Focus, 2026-01. Verfasst von Tamás Fazekas und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Semmelweis University, Buda…. Hauptthemen laut MEDLINE: Quality of Life, Prostatic Neoplasms, Androgen Receptor Antagonists, Androgen Antagonists. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencja Badań Medycznych, Narodowa Agencja Wymiany Akademickiej, European Association of Urology.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Androgen receptor pathway inhibitors (ARPIs) as monotherapy are studied increasingly across prostate cancer disease states. We aimed to evaluate the safety, oncologic efficacy, and quality of life (QoL) of ARPI monotherapy as compared with ARPI + androgen deprivation therapy (ADT) and ADT alone. METHODS: PubMed/Medline, Embase, and Cochrane/Central were queried through June 2024 for clinical trials. The primary outcomes were the rates of adverse events (AEs) presented as risk ratios (RRs); the secondary outcomes included efficacy and QoL. KEY FINDINGS AND LIMITATIONS: We synthesized data from 2015 men, retrieved from 17 studies. The incidence of any AEs was similar between patients on ARPIs, ARPI + ADT (RR: 1.01, 95% confidence interval [CI]: 1-1.02, p = 0.08), and ADT (RR: 1.01, 95% CI: 0.98-1.04, p = 0.3). The incidence of grade ≥3 AEs was higher in patients on ARPI monotherapy than in those on ADT (RR: 1.18, 95% CI: 1.11-1.24, p < 0.01), driven mainly by fatigue and cardiovascular toxicity. There was no statistically significant difference in grade ≥3 AEs between patients treated with ARPIs and ARPI + ADT (RR: 1.07, 95% CI: 0.87-1.3, p = 0.4). ARPI monotherapy led to a lower incidence of hot flushes (RR: 0.4, 95% CI: 0.18-0.89, p = 0.03) but higher incidences of breast pain (RR: 6.03, 95% CI: 3.34-10.88, p < 0.01) and gynecomastia (RR: 5.73, 95% CI: 3.79-8.66, p < 0.01) than treatment with ARPI + ADT. ARPIs demonstrated promising oncologic efficacy for patients with biochemical recurrence, while maintaining favorable overall and sexual QoL. CONCLUSIONS AND CLINICAL IMPLICATIONS: ARPI monotherapy results in overall similar toxicities for ARPI + ADT and ADT alone. The specific AE pattern of each combination can serve as a basis to tailor therapy to each patient's needs and wishes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Semmelweis University, Budapest, Hungary; Centre for Translational Medicine, Semmelweis Universit…
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Collegium Medicum, Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland.
- Department of Urology, University Hospitals Leuven, Leuven, Belgium; Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
- Centre for Translational Medicine, Semmelweis University, Budapest, Hungary; Department of Stochastics, Institute of Mathematics, Budapest University of Technology and Economics, Budapest, Hungary.
- Department of Surgery, Oncology, and Gastroenterology - Urology Clinic, University of Padua, Padua, Italy; Department of Medicine (DIMED), University of Padua, Padova, Italy.
- Department of Urology, Institut Mutualiste Montsouris, Paris, France.
Förderung
- Agencja Badań Medycznych
- Narodowa Agencja Wymiany Akademickiej
- European Association of Urology
- Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
Zitieren
APA
Fazekas, T., Miszczyk, M., Giesen, A., Kói, T., Zattoni, F., Rodriguez-Sanchez, L., Yanagisawa, T., Matsukawa, A., Szarvas, T., Kryst, P., Rivas, J. G., Merseburger, A. S., Santis, M., Joniau, S., Briganti, A., Marra, G., Nyirády, P., Gandaglia, G., Shariat, S. F., …, & EAU-YAU Prostate Cancer Working Group (2026). Androgen Receptor Pathway Inhibitor Monotherapy in Prostate Cancer: Safety, Oncologic Outcomes, and Quality of Life—A Systematic Review and Meta-analysis. European Urology Focus, 12(1), 109-130. https://doi.org/10.1016/j.euf.2025.05.006
Vancouver
Fazekas T, Miszczyk M, Giesen A, Kói T, Zattoni F, Rodriguez-Sanchez L, et al. Androgen Receptor Pathway Inhibitor Monotherapy in Prostate Cancer: Safety, Oncologic Outcomes, and Quality of Life—A Systematic Review and Meta-analysis. European Urology Focus. 2026;12(1):109-130. doi:10.1016/j.euf.2025.05.006
BibTeX
@article{Fazekas2026,
author = {Fazekas, Tamás and Miszczyk, Marcin and Giesen, Alexander and Kói, Tamás and Zattoni, Fabio and Rodriguez-Sanchez, Lara and Yanagisawa, Takafumi and Matsukawa, Akihiro and Szarvas, Tibor and Kryst, Piotr and Rivas, Juan Gómez and Merseburger, Axel S and Santis, Maria De and Joniau, Steven and Briganti, Alberto and Marra, Giancarlo and Nyirády, Péter and Gandaglia, Giorgio and Shariat, Shahrokh F and Rajwa, Pawel and EAU-YAU Prostate Cancer Working Group, EAU-YAU Prostate Cancer Working Group},
title = {Androgen Receptor Pathway Inhibitor Monotherapy in Prostate Cancer: Safety, Oncologic Outcomes, and Quality of Life—A Systematic Review and Meta-analysis},
journal = {European Urology Focus},
year = {2026},
volume = {12},
number = {1},
pages = {109--130},
doi = {10.1016/j.euf.2025.05.006}
}
EUVIMED